1.1Sulfur at the carbonyl site
Thionation of the ring carbonyl gives a pyridazinethione. The C=S group retains a trigonal ring carbon and presents a larger, more polarizable sulfur atom at the edge of the ring.
Generated automatically. Not reviewed by a person. Not legal advice or an opinion.
Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.
Thionation of the ring carbonyl gives a pyridazinethione. The C=S group retains a trigonal ring carbon and presents a larger, more polarizable sulfur atom at the edge of the ring.
The X1 carbon forms bonds to both neighboring ring atoms and contributes a p orbital to the conjugated core. Its C–H bond projects from the ring edge, and the ring carbonyl remains a hydrogen-bond acceptor.
Three consecutive methylene groups connect the core to R5 through single bonds. The extra methylene increases the maximum reach of the terminal ring and adds a rotatable carbon–carbon bond.
X2 and X3 each form a C–F bond and retain their positions in the conjugated ring. The two C–F bond dipoles change the electrostatic surface along that edge of the core.
The linker bonds to carbon 2 of a five-membered aromatic ring containing sulfur and nitrogen. The ring nitrogen supplies a hydrogen-bond acceptor, and the five-membered ring changes the angle between that acceptor and the linker.
Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.
An isolated pyridazinone with a pyridyl A group and a methylene-linked pyrazinyl R5 serves as a recovery tracer in a water-analysis laboratory. The laboratory adds the tracer to one water aliquot before solid-phase extraction and to a matched aliquot after extraction. Liquid chromatography measures both aliquots at the same final volume, and the ratio of their peak areas gives the fraction recovered during sample preparation.
A 5-methyl-1,2,4-oxadiazol-3-yl group replaces R5 at the end of a methylene linker. Ring carbon 3 bonds to the methylene carbon, and ring carbon 5 bears the methyl group. The pyridazinone carbonyl, the pyridyl A group, and the hydrogen atoms at R3 and R4 remain in place.
A methylene–oxygen–methylene linker replaces the hydrocarbon segment between the pyridazinone scaffold and a pyridin-3-yl R5 group. The scaffold bonds to the first methylene, and the second methylene bonds to carbon 3 of the pyridine ring. The ether oxygen adds a hydrogen-bond acceptor between the two methylene groups.
A two-member series uses three and four methylene units between the pyridazinone scaffold and a pyridin-3-yl terminal ring. Each member uses the same unsubstituted pyridyl A group and retains hydrogen at R3 and R4. The side chain bonds to the scaffold through its first carbon and to carbon 3 of the terminal pyridine through its last carbon.
A preparative reversed-phase liquid chromatograph separates pyridazinone derivatives on a column packed with octadecyl-bonded silica. An aqueous-to-acetonitrile gradient carries the separated components through an ultraviolet detector, and a split stream enters a mass spectrometer. The fraction collector opens a collection window when the target mass signal crosses a set threshold and applies a delay that accounts for transit from the stream split to the collection valve.
Software stores the pyridazinone scaffold as a molecular graph with attachment points for A and the R2 linker. It joins pyridyl and pyrimidinyl fragments to those points at each ring carbon bearing a replaceable hydrogen and generates regioisomers with one fluoro or methoxy substituent at a remaining ring carbon. It checks atom valences, removes duplicate structures using canonical graph identifiers, and exports a structure record and calculated molecular mass for each retained compound.
R2 is —CH2CH2–R5, with the first methylene bonded to the core and the second bonded to R5. Rotation about the bond between the methylenes changes the orientation of R5 relative to the core.
R5 is an unsubstituted pyrazin-2-yl group attached through carbon 2. Its two aromatic nitrogen atoms occupy opposite positions in the six-membered ring.
A is 5-fluoropyridin-3-yl and connects to the rest of the molecule through carbon 3. A single fluorine occupies carbon 5, and the pyridine nitrogen provides a hydrogen-bond acceptor.
Ra is trifluoromethyl, a one-carbon haloalkyl group with three fluorines on the same carbon. In ORa, oxygen connects the aromatic ring to that carbon to form an —OCF3 substituent.
Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.
Oxidation of the thioether with organic and inorganic oxidizing agents, such as m-chloroperbenzoic acid or oxone, yields the sulfones which, upon condensation with p-aminocarbonylanilines, give rise to the formation of the desired anilinopyrimidine derivatives.A · US 7,122,544 B2 · ¶ 67
R8, R9, R10, and R11 are the same or different and at each occurrence independently hydrogen, alkyl, substituted alkyl, phenyl or naphthyl, substituted phenyl or naphthyl, aralkyl, substituted arylalkyl, substituted or unsubstituted pyridyl, furyl, beazofuranyl, thiophenyl, benzothiophenyl, quinolinyl, pyrrolyl, indolyl, oxazolyl, benzoxazolyl, imidazolyl, benzimidazolyl, thiazolyl, beazothiazolyl, isoxazolyl, pyrazolyl, isothiazolyl, pyridazinyl, pyrimidinyl, pyrazinyl, triaA · US 7,122,544 B2 · claim 1
The aryl groups of the invention may optionally be substituted by one or more halogen atoms. Examples of aromatic moieties are benzene, naphthalene, imidazole and pyridine.B · US 2014/0073801 A1 · ¶ 90
A compound having the structure: or a pharmaceutically acceptable salt thereof, wherein: R1 is phenyl, naphthyl, benzofuranyl, thiophenyl, benzothiophenyl, quinolinyl, pyrrolyl, indolyl, oxazolyl, benzoxazolyl, imidazolyl, benzimidazolyl, thiazolyl, benzothiazolyl, isothiazolyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, cinnolinyl, phthalazinyl, or quinazolinyl, optionally substituted with one to four substituents independently selected from R7;A · US 7,122,544 B2 · claim 1
R4 represents one to four optional substituents, wherein each substituent is the same or different and independently selected from halogen, hydroxy, lower alkyl and lower alkoxy;A · US 7,122,544 B2 · claim 1
C1-15 alkyl or alkenyl optionally substituted with one or more OH, OR10, ═O, NH2, N3, SH, SOxR10, halo, CN, NO2, NR10R11, (NR10)NR10R11, NH(NR10)NR10R11, CO2R10, OC(O)R10, P(O)(OR10)2, aryl or carbocyclyl groups; carbocyclyl or aryl, either of which is optionally substituted with one or more OH, OR10, ═O, NH2, N3, SH, SO9R10, halo, CN, NO2, NR10R11, (NR10)NR10R11, NH(NR10)NR10R11, CO2R10, OC(O)R10, P(O)(OR10)2, C1-9 alkyl optionally substituted with one or more OH, OR10, ═O,B · US 2014/0073801 A1 · ¶
O-phosphate or a group which together with the endocyclic carbon forms a spiro ring R10 represents H; C1-6 alkyl, optionally substituted with one or more OH, halo; aryl or C1-4 alkyl optionally substituted with aryl; and R11 represents H;B · US 2014/0073801 A1 · ¶
An empty cell means only that no passage was reproduced there.
This invention is generally directed to anilinopyrimidine derivatives that have utility as IκB kinase (IKK) inhibitors, and particularly as IKK-2 inhibitors, as well to related compositions and methods.A · US 7,122,544 B2 · ¶ 2
IKK enzymes show relatively low sequence homologies with other kinases, and early profiles with known kinase inhibitors have not identified compounds with striking potency.A · US 7,122,544 B2 · ¶ 4
The invention relates to compounds, in particular iminosugars, methods of manufacture of the compounds, and the use of these compounds in the treatment of diseases or disorders responsive to inhibition of O-GlcNAcase.B · US 2014/0073801 A1 · ¶ 1
In particular, the invention relates to the use of an iminosugar compound a prodrug thereof and a pharmaceutical composition comprising the compound or the prodrug for selective inhibition of O-GlcNAcase enzymes including human OGA.B · US 2014/0073801 A1 · ¶ 1
patent.fyi, US 2026/0356816 A1, claim 1, first published 2026-11-20T07:31:16-05:00, https://patent.fyi/US20260356816/, SHA-256 c9216a64532375781407643055e9b86c4e35a5c8652f67286d1bb428cfd862f5